Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease

Movement Disorders

Volumn 27, Issue 2, 2012, Pages 288-293

  Schmid, Stefan P ^a,b   Schleicher, Erwin D ^b   Cegan, Alexander ^c   Deuschle, Christian ^a,b   Baur, Stephanie ^a,b   Hauser, Ann Kathrin ^a,b   Synofzik, Matthis ^a,b   Srulijes, Karin ^a,b   Brockmann, Kathrin ^a,b   Berg, Daniela ^a,b   Maetzler, Walter ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF PARDUBICE   (Czech Republic)

Author keywords

Alpha synuclein; Cerebrospinal fluid; Glucocerebrosidase gene; Polyunsaturated fatty acids

Indexed keywords

ARACHIDIC ACID; ARACHIDONIC ACID; BEHENIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; GLUCOSYLCERAMIDASE; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN; MYRISTIC ACID; PALMITIC ACID; PALMITOLEIC ACID; STEARIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; FATTY ACIDS; FEMALE; GLUCOSYLCERAMIDASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE;

EID: 84856975504     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23984     Document Type: Note

References (26)

1. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
2. Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Gen 2011; 20: 202-210.
3. Pastores GM. Gaucher's Disease. Pathological features. Bailliere's Clin Haematol 1997; 10: 739-749.
4. Conradi NG, Sourander P, Nilsson O et al. Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropath 1984; 65: 99-109.
5. Grafe M, Thomas C, Schneider J, et al. Infantile Gaucher's disease: a case with neuronal storage. Ann Neurol 1988; 23: 300-303.
6. Cervos-Navarro J, Zimmer C. Light microscopic and ultrastructural study on CNS lesions in infantile Gaucher's disease. Clin Neuropath 1990; 9: 310-313.
7. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Gen Metabol 2004; 82: 192-207.
8. Campeau PM, Rafei M, Boivin MN, et al. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 2009; 114: 3181-3190.
9. Mutch DM, O'Maille G, Wikoff WR, et al. Mobilization of pro-inflammatory lipids in obese Plscr3-deficient mice. Gen Biol 2007; 8: R38.
10. Falomir Lockhart LJ, Burgardt NI, Ferreyra RG, et al. Fatty acid transfer from Yarrowia lipolytica sterol carrier protein 2 to phospholipid membranes. Biophys J 2009; 97: 248-256.
11. Uc EY, Struck LK, Rodnitzky RL, et al. Predictors of weight loss in Parkinson's disease. Mov Disord 2006; 21: 930-936.
12. Julien C, Berthiaume L, Hadj-Tahar A, et al. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int 2006; 48: 404-414.
13. Assayag K, Yakunin E, Loeb V, et al. Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol 2007; 171: 2000-2011.
14. Barcelo-Coblijn G, Golovko MY, Weinhofer I, et al. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem 2007; 101: 132-141.
15. Castagnet PI, Golovko MY, Barcelo-Coblijn GC, et al. Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J Neurochem 2005; 94: 839-849.
16. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132: 1783-1794.
17. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropath 2010; 120: 641-649.
18. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. JNNP 1988; 51: 745-752.
19. Maetzler W, Schmid SP, Wurster I, et al. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 2011; 26: 176-181.
20. Maetzler W, Keller S, Michelis J, et al. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 2009; 35: 296-301.
21. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83: 1505S-1519S.
22. Cherubini A, Andres-Lacueva C, Martin A, et al. Low plasma N-3 fatty acids and dementia in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2007; 62: 1120-1126
23. Whelan J. (n-6) and (n-3) Polyunsaturated fatty acids and the aging brain: food for thought. J Nutr 2008; 138: 2521-2522.
24. Fukaya T, Gondaira T, Kashiyae Y et al. Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. Neurobiol Aging 2007; 28: 1179-1186.
25. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Resh 2010; 35: 503-513.
26. Gan-Or Z, Giladi N, Orr-Urtreger A. Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations. Brain 2009; 132: e125.